Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses

Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses

Abstract Nowadays medulloblastoma (MB) tumors can be treated with risk-stratified approaches with up to 80% success rate. However, disease relapses occur in approximately 30% of patients and successful salvage treatment strategies at relapse remain scarce. Acquired copy number changes or TP53 mutati...

Full description

Bibliographic Details
Main Authors: Konstantin Okonechnikov, Aniello Federico, Daniel Schrimpf, Philipp Sievers, Felix Sahm, Jan Koster, David T. W. Jones, Andreas von Deimling, Stefan M. Pfister, Marcel Kool, Andrey Korshunov
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Acta Neuropathologica Communications
Subjects:
Medulloblastoma
Relapses
Transcriptomics
Prognosis
Online Access:https://doi.org/10.1186/s40478-023-01504-1

Internet

https://doi.org/10.1186/s40478-023-01504-1

Similar Items